Dr. Hem A. Deodhar, MD

Dr. Deodhar practices at Ngc Endoscopy Services, LLC - HOPD in Portland, Oregon.

Dr. Deodhar's NPI, 1497723555, was assigned on March 14, 2006. Dr. Deodhar holds Oregon license MD21331.

Dr. Deodhar's primary practice is Ngc Endoscopy Services, LLC - HOPD, at 1130 Nw 22nd Ave, Portland, OR 97210.

Dr. Deodhar's primary practice is Ngc Endoscopy Services, LLC - HOPD in Portland, Oregon. Dr. Deodhar is also affiliated with OHSU Hospital. The medical group on file is Northwest Renal Clinic. Dmand AI also links Dr. Deodhar to 4 more hospitals, 3 dialysis centers, 1 group practice or clinic and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deodhar practices, 11 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Deodhar's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Deodhar is licensed in Oregon.

CMS data shows 761 Medicare services from Dr. Deodhar across 14 procedure codes in 2024, for 294 Medicare patients. Medicare paid $76,872 for them.

CMS counts 294 Medicare patients who saw Dr. Deodhar in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 34% are also on Medicaid. Their average risk score is 6.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Deodhar's median patient age at 68, with 43% women.

In 2024, Dr. Deodhar wrote 1,364 Medicare Part D claims for 300 patients. 90% of them were for generic drugs. CMS names the drug for 1,019 of them, across 31 drugs with 11 or more claims each, at $136,585 in total drug cost. In 2023, CMS named 1,088 claims across 31 drugs.

Dr. Deodhar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Deodhar as offering telehealth.

CMS Open Payments shows 37 general payments to Dr. Deodhar from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Novartis Pharmaceuticals Corporation paid the most, $621.